Aiming to study the capacity of RhoC-specific CD4+ T cells to kill cancer cells, we generated RV001-specific CD4+ T cells both from a healthy donor (after in vitro priming with autologous DCs loaded with the RV001 peptide) and from a vaccinated patient (after short recall culture in the presence of RV001). This evidence concerns the gene CD4 and cancer.